Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable ...

Financial Results Q1 2025 PLAY's business plan continues to progress, with a clear focus on our most stable and profitable business segments: leisure and ACMI operations.Cash position strengthened ...

PLAY carried 286 thousand passengers in the first quarter of 2025, compared to 349 thousand passengers during the same period in 2024. The load factor in Q1 2025 was 77.2%, compared to 81.8% in Q1 ...

Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignancies ...

Brendan Cavanagh; President, Chief Executive Officer, Director; SBA Communications Corp Marc Montagner; Chief Financial Officer, Executive Vice President; SBA Communications Corp Thank you. Good ...

Q1 2025 Earnings Call Transcript April 25, 2025 Operator: Good afternoon. Welcome to the First Business Financial Services ...

Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update <li /> Successful s ...